6β-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice

Life Sciences

Volumn 85, Issue 11-12, 2009, Pages 413-420

  Yancey Wrona, Janet E ^a   Raymond, Tyler J ^b   Mercer, Hannah K ^b   Sadée, Wolfgang ^c   Bilsky, Edward J ^b  

^a AIKO Biotechnology   (United States)

^b UNIVERSITY OF NEW ENGLAND   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

6 naltrexol; Gastrointestinal transit; Hydrocodone; Naltrexone; Opioid antagonist

Indexed keywords

CHARCOAL; HYDROCODONE; NALTREXOL; NALTREXONE; OPIATE RECEPTOR; 6 BETA HYDROXYNALTREXONE; 6 BETA-HYDROXYNALTREXONE; DRUG DERIVATIVE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG ANTAGONISM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG POTENCY; DRUG STRUCTURE; FOOD INTAKE; GASTROINTESTINAL TRANSIT; IN VIVO STUDY; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; TAIL FLICK TEST; TIME; ANIMAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PAIN ASSESSMENT; REACTION TIME;

MUS;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GASTROINTESTINAL TRANSIT; HYDROCODONE; INJECTIONS, INTRAVENOUS; MALE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; PAIN MEASUREMENT; REACTION TIME;

EID: 69349087316     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.06.016     Document Type: Article

References (28)

1. Baum C., Hsu J.P., and Nelson R.C. The impact of the addition of naloxone on the use and abuse of pentazocine. Public Health Report 102 4 (1987) 426-429
2. Berde C., and Nurko S. Opioid side effects-Mechanism-based therapy. New England Journal of Medicine 358 22 (2008) 2400-2402
3. Bilsky E.J., Qian X., Hruby V.J., and Porreca F. Antinociceptive activity of [beta-methyl-2′, 6′-dimethyltyrosine(1)]-substituted cyclic [D-Pen(2), D-Pen(5)]Enkephalin and [D-Ala(2),Asp(4)]Deltorphin analogs. Journal of Pharmacology and Experimental Therapeutics 293 1 (2000) 151-158
4. Boyd T.A., and Yuan C.S. Methylnaltrexone: Investigations in treating opioid bowel dysfunction (chapter 10). In: Yuan C.S. (Ed). Handbook of Opioid Bowel Syndrome (2005), Haworth Medical Press
5. Crabtree B.L. Review of naltrexone, a long-acting opiate antagonist. Clinical Pharmacology 3 3 (1984) 273-280
6. Culpepper-Morgan J.A., Inturrisi C.E., Portenoy R.K., Foley K., Houde R.W., Marsh F., and Kreek M.J. Treatment of opioid-induced constipation with p.o. naloxone: A pilot study. Clinical Pharmacology and Therapeutics 52 1 (1992) 90-95
7. Cunningham C.W., Mercer S.L., Hassan H.E., Traynor J.R., Eddington N.D., and Coop A. Opioids and efflux transporters. Part 2: P-glycoprotein substrate activity of 3- and 6-substituted morphine analogs. Journal of Medicinal Chemistry 51 7 (2008) 2316-2320
8. Foss J.F., and Schmidt W.K. Management of opioid-induced bowel dysfunction and postoperative ileus: Potential role of alvimopan (chapter 11). In: Yuan C.S. (Ed). Handbook of Opioid Bowel Syndrome (2005), Haworth Medical Press
9. Gutstein H.B., and Akil H. Opioid analgesics (chapter 21). In: Brunton L. (Ed). Goodman and Gilman's The Pharmacological Basis of Therapeutics. eleventh ed. (2006), McGraw-Hill
10. Leslie J.B. Alvimopan: A peripherally acting mu-opioid receptor antagonist. Drugs of Today (Barcelona) 43 9 (2007) 611-625
11. Liu M., and Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. Journal of Pain and Symptom Management 23 1 (2002) 48-53
12. Manchikanti L. National drug control policy and prescription drug abuse: Facts and fallacies. Pain Physician 10 3 (2007) 399-424
13. Manchikanti L., and Singh A. Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 11 2 Suppl (2008) S63-88
14. McNicol E.D., Boyce D., Schumann R., and Carr D.B. Mu-opioid antagonists for opioid-induced bowel dysfunction. Cochrane Database of Systematic Reviews 2 (2008) CD006332
15. Mendelson J., and Jones R.T. Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: Why the 4:1 ratio for treatment?. Drug and Alcohol Dependence 70 2S (2003) S29-S37
16. Mercer S.L., Cunningham C.W., Eddington N.D., and Coop A. Opioids and efflux transporters. Part 3: P-glycoprotein substrate activity of 3-hydroxyl addition to meperidine analogs. Bioorganic & Medicinal Chemistry Letters 18 12 (2008) 3638-3640
17. Mercer S.L., Hassan H.E., Cunningham C.W., Eddington N.D., and Coop A. Opioids and efflux transporters. Part 1: P-glycoprotein substrate activity of N-substituted analogs of meperidine. Bioorganic & Medicinal Chemistry Letters 17 5 (2007) 1160-1162
18. Misra A.L. Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone. NIDA Research Monograph 28 (2001) 132-146
19. Perry D.C., Mullis K.B., Oie S., and Sadée W. Opiate antagonist receptor binding in vivo: Evidence for a new receptor binding model. Brain Research 199 1 (1980) 49-61
20. Porter S.J., Somogyi A.A., and White J.M. Kinetics and inhibition of the formation of 6β-naltrexol from naltrexone in human liver cytosol. British Journal of Clinical Pharmacology 50 5 (2000) 465-471
21. Raehal K.M., Lowery J.J., Bhamidipati C.M., Paolino R.M., Blair J.R., Wang D., Sadée W., and Bilsky E.J. In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice. Journal of Pharmacology and Experimental Therapeutics 313 3 (2005) 1150-1162
22. Reichle F.M., and Conzen P.F. Methylnaltrexone, a new peripheral mu-receptor antagonist for the prevention and treatment of opioid-induced extracerebral side effects. Current Opinion in Investigational Drugs 9 1 (2008) 90-100
23. Rollason V., Samer C., Piguet V., Dayer P., and Desmeules J. Pharmacogenetics of analgesics: Toward the individualization of prescription. Pharmacogenomics 9 7 (2008) 905-933
24. Sadée W., Wang D., and Bilsky E.J. Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities. Life Sciences 76 13 (2005) 1427-1437
25. Simojoki K., Vorma H., and Alho H. A retrospective evaluation of patients switched from buprenorphine (Subutex) to the buprenorphine/naloxone combination (Suboxone). Substance Abuse Treatment, Prevention, and Policy 3 (2008) 16
26. Tofil N.M., Benner K.W., Faro S.J., and Winkler M.K. The use of enteral naloxone to treat opioid-induced constipation in a pediatric intensive care unit. Pediatric Critical Care Medicine 7 3 (2006) 252-254
27. Wang D., Raehal K.M., Bilsky E.J., and Sadée W. Inverse agonists and neutral antagonists at mu opioid receptor (MOR): Possible role of basal receptor signaling in narcotic dependence. Journal of Neurochemistry 77 6 (2001) 1590-1600
28. Wang D., Raehal K.M., Lin E.T., Lowery J.J., Kieffer B.L., Bilsky E.J., and Sadée W. Basal signaling activity of mu opioid receptor in mouse brain: Role in narcotic dependence. Journal of Pharmacology and Experimental Therapeutics 308 2 (2004) 512-520